Varenicline and Bupropion for Long-Term Smoking Cessation (the MATCH Study): Protocol for a Real-World, Pragmatic, Randomized Controlled Trial

Laurie Zawertailo, Tara Mansoursadeghi-Gilan, Helena Zhang, Sarwar Hussain, Bernard Le Foll, Peter Selby, Laurie Zawertailo, Tara Mansoursadeghi-Gilan, Helena Zhang, Sarwar Hussain, Bernard Le Foll, Peter Selby

Abstract

Background: Varenicline and bupropion are efficacious, prescription-only pharmacotherapies for smoking cessation; however, their real-world impact is limited by prescriber knowledge, affordability, and accessibility.

Objective: The primary objective of the MATCH (Medication Aids for Tobacco Cessation Health) study was to evaluate the real-world, long-term effectiveness of mailed bupropion and varenicline in a sample of interested smokers with the utilization of Web-based recruitment and follow-up. In addition, the study aims to investigate the genotypic and phenotypic predictors of cessation.

Methods: This is a two-group, parallel block, randomized (1:1) open-label clinical trial. This study will be conducted online with the baseline enrollment through the study's website and follow-up by emails. In addition, medication prescriptions will be filled by the study contract pharmacy and couriered to participants. Individuals who smoke ≥10 cigarettes per day and intend to quit within the next 30 days will be recruited through Public Health Units and Tobacco Control Area Networks throughout Ontario by word-of-mouth and the internet. Eligible participants will receive an email with a prescription for 12-week assigned medication and a letter to take to their physician. The recruitment and randomization will continue until 500 participants per arm have received medication. All participants will receive weekly motivational emails during the treatment phase. The primary outcome measure is the smoking status after 6 months, biochemically confirmed by mailed-in salivary cotinine. Follow-ups will be conducted through emails after 4, 8, 12, 26, and 52 weeks of starting the treatment to assess the smoking prevalence and continuous smoking abstinence. In addition, mailed-in saliva samples will be used for genetic and nicotine metabolism analyses. Furthermore, personality characteristics will be assessed using the Big Five Aspect Scales.

Results: The project was funded in 2014 and enrollment was completed in January 2017. Data analysis is currently underway.

Conclusions: To the best of our knowledge, this is the first randomized controlled trial to mass distribute prescription medications for smoking cessation. We expect this method to be logistically feasible and cost effective with quit outcomes that are comparable to published clinical trials.

Trial registration: ClinicalTrials.gov NCT02146911; https://ichgcp.net/clinical-trials-registry/NCT02146911 (Archived by WebCite at http://www.webcitation.org/72CZ6AvXZ).

Registered report identifier: RR1-10.2196/10826.

Keywords: bupropion; genetics; internet; personality traits; smoking cessation; tobacco; varenicline.

Conflict of interest statement

Conflicts of Interest: Over the last 5 years, PS has received grants from Pfizer Inc, Shoppers Drug Mart, Bhasin Consulting Fund Inc, and Patient-Centered Outcomes Research Institute. BLF receives support from Pfizer Global Research Awards in Nicotine Dependence Award Program.

©Laurie Zawertailo, Tara Mansoursadeghi-Gilan, Helena Zhang, Sarwar Hussain, Bernard Le Foll, Peter Selby. Originally published in JMIR Research Protocols (http://www.researchprotocols.org), 18.10.2018.

Figures

Figure 1
Figure 1
An overview of the proposed intervention trial (CONSORT [Consolidated Standards of Reporting Trials] diagram).
Figure 2
Figure 2
Participants’ flowchart. BFAS: Big Five Aspect Scale.

References

    1. Health Canada Canadian Tobacco Use Monitoring Survey (CTUMS) 2012 March. 2013. p. 31. .
    1. Rehm JB, Brochu S, Fischer B, Gnam W, Patra J. The costs of substance abuse in Canada. Ottawa: Canadian Centre on Substance Abuse. 2006;Ottawa
    1. Lancaster T, Stead L, Silagy C, Sowden A. Effectiveness of interventions to help people stop smoking: findings from the Cochrane Library. BMJ. 2000 Aug 05;321(7257):355–8.
    1. Silagy C, Lancaster T, Stead L, Mant D, Fowler G. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev. 2004 doi: 10.1002/14651858.CD000146.pub2.
    1. Hughes JR, Stead LF, Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev. 2007 doi: 10.1002/14651858.CD000031.pub3.
    1. Gonzales D, Rennard Stephen I, Nides Mitchell, Oncken Cheryl, Azoulay Salomon, Billing Clare B, Watsky Eric J, Gong Jason, Williams Kathryn E, Reeves Karen R, Varenicline Phase 3 Study Group Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA. 2006 Jul 05;296(1):47–55. doi: 10.1001/jama.296.1.47.
    1. Jorenby D, Hays J Taylor, Rigotti Nancy A, Azoulay Salomon, Watsky Eric J, Williams Kathryn E, Billing Clare B, Gong Jason, Reeves Karen R, Varenicline Phase 3 Study Group Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA. 2006 Jul 05;296(1):56–63. doi: 10.1001/jama.296.1.56.
    1. Nides M, Oncken Cheryl, Gonzales David, Rennard Stephen, Watsky Eric J, Anziano Rich, Reeves Karen R. Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up. Arch Intern Med. 2006;166(15):1561–8. doi: 10.1001/archinte.166.15.1561.
    1. Health Canada. 2007. [2018-09-11]. Canadian Tobacco Use Monitoring Survey: Annual, Person File .
    1. Stevenson JS, Kaiserman MJ. CDC. [2018-09-11]. Smoking-cessation advice from health-care providers-Canada .
    1. Gollust S, Schroeder Steven A, Warner Kenneth E. Helping smokers quit: understanding the barriers to utilization of smoking cessation services. Milbank Q. 2008 Dec;86(4):601–27. doi: 10.1111/j.1468-0009.2008.00536.x.
    1. Costello M, Sproule Beth, Victor J Charles, Leatherdale Scott T, Zawertailo Laurie, Selby Peter. Effectiveness of pharmacist counseling combined with nicotine replacement therapy: a pragmatic randomized trial with 6,987 smokers. Cancer Causes Control. 2011 Feb;22(2):167–80. doi: 10.1007/s10552-010-9672-9.
    1. Zawertailo L, Bondy S, Victor C, Selby P. Reach and effectiveness of mailed nicotine replacement therapy for smokers: six-month outcomes in a naturalistic, exploratory study. Tobacco Control. 2012
    1. DeYoung C, Quilty Lena C, Peterson Jordan B. Between facets and domains: 10 aspects of the Big Five. J Pers Soc Psychol. 2007 Nov;93(5):880–96. doi: 10.1037/0022-3514.93.5.880.
    1. Heatherton. Kozlowski L T, Frecker R C, Fagerström K O. The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire. Br J Addict. 1991 Sep;86(9):1119–27.
    1. Kroenke K, Spitzer R L, Williams J B. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001 Sep;16(9):606–13.
    1. Dempsey D, Tutka P, Jacob P, Allen F, Schnoedel K, Tyndale RF, Benowitz NL. Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity. Clin Pharmacol Ther. 2004 doi: 10.1016/j.clpt.2004.02.011.
    1. Zawertailo L, Hussain H, Selby P. Using the internet to distribute prescription smoking cessation medications: six-month outcomes. Society for Research on Nicotine Tobacco Annual Meeting, March 13-16, Houston, TX. 2012
    1. Selby P, Hussain H, Voci S, Zawertailo L. Empowering smokers with a web-assisted tobacco intervention to use prescription smoking cessation medications: a feasibility trial. Implement Sci. 2015:a. doi: 10.1186/s13012-015-0329-7.
    1. Krueger H, Koot J. Variation across Canada in the economic burden attributable to excess weight, tobacco smoking and physical inactivity. Can J Public Health. 2015 doi: 10.17269/cjph.106.4994.
    1. Society for Research on Nicotine and Tobacco Biochemical verification of tobacco use and cessation. Nicotine Tob Res. 2002 doi: 10.1080/14622200210123581.

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera